Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14)
Silke Gillessen, Katrin Gobat, R. Cathomas, Natalie Fischer et autres
Background and objective The aim of our study is to determine whether the addition of metformin to enzalutamide can improve the outcomes of men with metastatic castration-resistant prostate cancer (mCRPC). Methods From 2016 to 2021, patients with mCRPC were randomized to receive …
ch, au, ca (code pays fourni par la source)
3 citations
European Urology Oncology